Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ONCT

Oncternal Therapeutics Inc

Dec 08 • 04:00PM ET

0.4310

Dollar change +0.0856
Percentage change 24.78	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.72	Insider Own	9.67%	Shs Outstand	57.46M	Perf Week	26.02%
Market Cap	25.42M	Forward P/E	-	EPS next Y	-0.56	Insider Trans	0.49%	Shs Float	53.27M	Perf Month	30.69%
Income	-41.72M	PEG	-	EPS next Q	-0.15	Inst Own	17.26%	Short Float / Ratio	0.81% / 2.80	Perf Quarter	36.70%
Sales	0.66M	P/S	38.51	EPS this Y	20.24%	Inst Trans	-14.47%	Short Interest	0.43M	Perf Half Y	34.02%
Book/sh	0.63	P/B	0.69	EPS next Y	16.04%	ROA	-69.89%	Target Price	2.17	Perf Year	-59.72%
Cash/sh	0.68	P/C	0.63	EPS next 5Y	0.00%	ROE	-79.05%	52W Range	0.26 - 1.33	Perf YTD	-56.90%
Dividend	-	P/FCF	-	EPS past 5Y	41.49%	ROI	-112.18%	52W High	-67.59%	Beta	1.24
Dividend %	-	Quick Ratio	8.25	Sales past 5Y	-0.45%	Gross Margin	72.08%	52W Low	65.13%	ATR	0.04
Employees	30	Current Ratio	8.25	Sales Q/Q	-53.14%	Oper. Margin	-6675.72%	RSI (14)	64.32	Volatility	17.32% 11.86%
Optionable	Yes	Debt/Eq	0.01	EPS Q/Q	18.52%	Profit Margin	-6330.05%	Rel Volume	2.61	Prev Close	0.35
Shortable	Yes	LT Debt/Eq	0.01	Earnings	Nov 09 AMC	Payout	-	Avg Volume	154.90K	Price	0.43
Recom	1.50	SMA20	27.22%	SMA50	33.34%	SMA200	7.47%	Volume	405,054	Change	24.78%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-07-21	Initiated	Oppenheimer	Outperform	$14
Feb-23-21	Initiated	Northland Capital	Outperform	$21

Nov-11-23 11:06AM	Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-09-23 04:01PM	Oncternal Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results (GlobeNewswire) -9.07%
Nov-02-23 04:05PM	Oncternal Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-26-23 09:00AM	Oncternal Therapeutics Announces FDA Granted Fast Track Designation for ONCT-534 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (GlobeNewswire)
Oct-25-23 09:00AM	Oncternal Therapeutics Adds Matthew Smith, M.D., Ph.D. to its Prostate Cancer Scientific Advisory Board (GlobeNewswire)
04:01PM	Loading…
Oct-05-23 04:01PM	Oncternal Therapeutics Announces First Patient Dosed in Phase 1/2 Study of Dual-Action AR Inhibitor, ONCT-534, in Patients with Metastatic Castration-Resistant Prostate Cancer (GlobeNewswire)
Sep-07-23 09:00AM	Oncternal Therapeutics Announces its Prostate Cancer Scientific Advisory Board (GlobeNewswire)
Aug-10-23 04:01PM	Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2023 Financial Results (GlobeNewswire) -6.71%
Aug-03-23 04:30PM	Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results (GlobeNewswire)
04:05PM	Oncternal Therapeutics Receives FDA Study May Proceed Letter for ONCT-534, its Novel Dual-action Androgen Receptor Inhibitor, for the Treatment of Patients with Advanced Prostate Cancer (GlobeNewswire)
Jul-26-23 01:30PM	Northland Capital Markets Institutional Investor Conference (ACCESSWIRE)
Jun-30-23 04:30PM	Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-06-23 04:01PM	Oncternal Therapeutics Announces First Patient Dosed in Phase 1/2 Study of ROR1 targeting autologous CAR T, ONCT-808, in patients with relapsed or refractory aggressive B-cell lymphoma (GlobeNewswire)
May-31-23 05:00PM	Oncternal Therapeutics to Participate at the 2023 Jefferies Healthcare Conference (GlobeNewswire)
May-06-23 08:14AM	Oncternal Therapeutics First Quarter 2023 Earnings: Revenues Beat Expectations, EPS In Line (Simply Wall St.)
04:01PM	Loading…
May-04-23 04:01PM	Oncternal Therapeutics Provides Business Update and Announces First Quarter 2023 Financial Results (GlobeNewswire)
Apr-27-23 05:00PM	Oncternal Therapeutics to Provide Business Update and Report First Quarter 2023 Financial Results (GlobeNewswire) +6.62%
Apr-17-23 06:54AM	Daily Vickers Top Buyers & Sellers for 04/17/2023 (Argus Research) +14.57%
Apr-13-23 05:00PM	Oncternal Therapeutics Participating in Oppenheimer & Co.s Virtual Fireside Chat: Discussion of ROR1 CAR T Cell Therapy in Hematological Malignancies and Solid Tumors (GlobeNewswire)
Apr-03-23 04:01PM	Oncternal Therapeutics Announces Strategic Reprioritization and Capital Preservation, Extends Cash Runway into 2025 (GlobeNewswire)
Mar-27-23 09:00AM	Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -8.39%
Mar-11-23 03:14AM	Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-09-23 04:01PM	Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Mar-02-23 05:00PM	Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Mar-01-23 05:00PM	Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-01-23 05:00PM	Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-04-23 04:05PM	Oncternal Therapeutics Announces the Appointment of Jill DeSimone to the Board of Directors (GlobeNewswire)
Jan-03-23 05:00PM	Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-10-22 03:00PM	Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib at ASH 2022 (GlobeNewswire)
Dec-01-22 05:00PM	Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
05:00PM	Loading…
Nov-14-22 05:00PM	Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.21%
Nov-03-22 04:01PM	Oncternal Therapeutics Provides Business Update and Announces Third Quarter 2022 Financial Results (GlobeNewswire)
09:05AM	Oncternal Therapeutics to Present Updated Interim Phase 1/2 Data for Zilovertamab in Combination with Ibrutinib in an Oral Session at ASH 2022 (GlobeNewswire)
Oct-27-22 05:53PM	Oncternal Therapeutics to Provide Business Update and Report Third Quarter 2022 Financial Results (GlobeNewswire)
Oct-03-22 05:30PM	Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +8.80%
04:31PM	Oncternal Therapeutics Receives IND Clearance for ONCT-808, its autologous CAR T Product Candidate Targeting ROR1 for the Treatment of Aggressive B Cell Lymphoma (GlobeNewswire)
Sep-27-22 09:00AM	Oncternal Therapeutics Initiates Global Registrational Phase 3 Study of Zilovertamab for Patients with MCL (GlobeNewswire)
Sep-23-22 09:00AM	Oncternal Therapeutics to Participate in the Cantor Oncology, Hematology & HemeOnc Conference (GlobeNewswire)
Sep-07-22 05:00PM	Oncternal Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-09-22 04:05PM	Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2022 Financial Results (GlobeNewswire)
Aug-02-22 05:00PM	Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2022 Financial Results (GlobeNewswire)
Jul-26-22 07:34AM	The past three years for Oncternal Therapeutics (NASDAQ:ONCT) investors has not been profitable (Simply Wall St.)
Jul-14-22 04:01PM	Oncternal Therapeutics Announces Clinical Trial Collaboration to Advance Zilovertamab Phase 3 Study in combination with Ibrutinib for Patients with MCL (GlobeNewswire)
Jun-10-22 04:30PM	Oncternal Therapeutics Presents New Preclinical Data from its anti-ROR1 Cell Therapy Collaboration with the Karolinska Institutet at the EHA2022 Congress (GlobeNewswire) -13.99%
09:00AM	Oncternal Therapeutics Presents Rationale and Plans for its Registrational Phase 3 Study Evaluating Zilovertamab in Combination with Ibrutinib at the EHA 2022 Congress (GlobeNewswire)
Jun-02-22 09:00AM	Oncternal Therapeutics to Participate in the Jefferies Healthcare Conference 2022 (GlobeNewswire)
Jun-01-22 05:00PM	Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.41%
May-26-22 05:15PM	Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib at ASCO 2022 (GlobeNewswire)
May-17-22 07:40AM	Here's Why We're Watching Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Situation (Simply Wall St.) +12.90%
May-05-22 04:01PM	Oncternal Therapeutics Provides Business Update and Announces First Quarter 2022 Financial Results (GlobeNewswire)
May-02-22 05:00PM	Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +23.05%
Apr-28-22 05:00PM	Oncternal Therapeutics to Provide Business Update and Report First Quarter 2022 Financial Results (GlobeNewswire)
03:02PM	Oncternal Therapeutics (ONCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Apr-13-22 08:30AM	Oncternal Therapeutics Deprioritizes Development of ONCT-216 to Focus Resources on Phase 3 Trial for Zilovertamab in the Treatment of Mantle Cell Lymphoma (GlobeNewswire)
Apr-01-22 05:00PM	Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-10-22 04:01PM	Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire)
Mar-07-22 05:00PM	Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire)
Mar-01-22 05:00PM	Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-16-22 10:11AM	Oncternal Therapeutics (NASDAQ:ONCT) investors are sitting on a loss of 75% if they invested a year ago (Simply Wall St.)
Jan-20-22 04:05PM	Oncternal Therapeutics Hosting Key Opinion Leader Webinar on Hematological Malignancies and Prostate Cancer (GlobeNewswire) -5.83%
Jan-19-22 05:38PM	Traverso Chambers Private Wealth Management, LLC Buys WisdomTree U.S. ... (GuruFocus.com)
Jan-04-22 04:01PM	Oncternal Therapeutics Announces Agreement with U.S. FDA on Phase 3 Registrational Study Design for Zilovertamab in the Treatment of Mantle Cell Lymphoma (GlobeNewswire)
Dec-14-21 08:53AM	Is Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Popular Amongst Institutions? (Simply Wall St.)
Dec-13-21 08:00AM	Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib at ASH 2021 (GlobeNewswire) -7.25%
Dec-01-21 05:00PM	Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.08%
Nov-15-21 08:00AM	Oncternal Therapeutics Presented Updated Interim Phase 1/2 Clinical Trial Data for ONCT-216 in Patients with Relapsed/Refractory Ewing Sarcoma at CTOS 2021 Virtual Annual Meeting (GlobeNewswire)
Nov-09-21 05:00PM	Oncternal Therapeutics to Present at the 12th Annual Jefferies London Healthcare Conference (GlobeNewswire)
Nov-04-21 04:05PM	Oncternal Provides Business Update and Announces Third Quarter 2021 Financial Results (GlobeNewswire) +6.54%
Nov-03-21 05:00PM	Oncternal Therapeutics Joins Karolinska Institutets NextGenNK Competence Center for the Development of Next Generation NK Cell-Based Cancer Immunotherapies (GlobeNewswire)
Nov-02-21 05:00PM	Oncternal Therapeutics Announces Formation of Cell Therapy Scientific Advisory Board (GlobeNewswire)
Nov-01-21 04:05PM	Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.45%
Oct-29-21 08:00AM	Oncternal Therapeutics to Provide Business Update and Report Third Quarter 2021 Financial Results (GlobeNewswire)
Oct-27-21 03:03PM	Will Oncternal Therapeutics (ONCT) Report Negative Q3 Earnings? What You Should Know (Zacks)
Oct-15-21 10:51AM	Companies Like Oncternal Therapeutics (NASDAQ:ONCT) Are In A Position To Invest In Growth (Simply Wall St.)
Oct-05-21 04:05PM	Oncternal Therapeutics Announced Pre-Clinical Data from ONCT-534, an Androgen Receptor N-Terminal-Domain-Binding Small Molecule Degrader, Was Accepted for Virtual Poster Presentation at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Oct-01-21 04:01PM	Oncternal Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-20-21 08:00AM	Oncternal Therapeutics and Celularity Enter into Research Collaboration to Evaluate Targeted Placental-Derived Cellular Therapies (GlobeNewswire) -7.31%
08:00AM	Celularity and Oncternal Therapeutics Enter into Research Collaboration to Evaluate Targeted Placental-Derived Cellular Therapies (GlobeNewswire)
Sep-09-21 04:01PM	Oncternal Therapeutics to Participate in September Investor Conferences (GlobeNewswire)
Sep-01-21 04:01PM	Oncternal Therapeutics Rounds Out Leadership Team with Appointment of Steven Hamburger, Ph.D. as Senior Vice President, Regulatory Affairs and Quality Assurance (GlobeNewswire)
Aug-16-21 01:17PM	Oncternal Therapeutics (NASDAQ:ONCT) pulls back 13% this week, but still delivers shareholders respectable 33% return over 1 year (Simply Wall St.) -5.69%
Aug-05-21 04:01PM	Oncternal Provides Business Update and Announces Second Quarter 2021 Financial Results (GlobeNewswire)
Aug-02-21 04:05PM	Oncternal Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
04:04PM	Oncternal Therapeutics to Participate in the BTIG Virtual Biotechnology Conference (GlobeNewswire)
Jul-29-21 03:05PM	Will Oncternal Therapeutics (ONCT) Report Negative Q2 Earnings? What You Should Know (Zacks)
08:00AM	Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2021 Financial Results (GlobeNewswire)
Jul-01-21 04:05PM	Oncternal Therapeutics Appoints Pablo Urbaneja as Sr. Vice President, Corporate Development (GlobeNewswire)
Jun-01-21 04:05PM	Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-31-21 05:02AM	Could The Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Ownership Structure Tell Us Something Useful? (Simply Wall St.)
May-26-21 08:00AM	Oncternal Therapeutics to Participate in Jefferies Virtual Healthcare Conference (GlobeNewswire) +7.78%
May-19-21 05:30PM	Oncternal Therapeutics Presents Updated Interim Data for TK216 in Patients with Relapsed or Refractory Ewing Sarcoma in an Oral Session at ASCO 2021 (GlobeNewswire)
05:01PM	Oncternal Therapeutics Presents Updated Interim Data for Cirmtuzumab in Combination with Ibrutinib at ASCO 2021 (GlobeNewswire)
May-17-21 04:01PM	Oncternal Therapeutics Announces Appointment of Salim Yazji as Chief Medical Officer (GlobeNewswire) +6.43%
May-06-21 04:01PM	Oncternal Provides Business Update and Announces First Quarter 2021 Financial Results (GlobeNewswire) -9.02%
May-03-21 04:01PM	Oncternal Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-29-21 04:01PM	Oncternal Therapeutics to Report First Quarter 2021 Financial Results and Provide Business Update (GlobeNewswire)
Apr-28-21 10:00AM	Oncternal Therapeutics Announces Presentation of Two Abstracts at ASCO 2021 Virtual Meeting (GlobeNewswire)
Apr-20-21 08:24PM	The Recent Pullback in These 3 Stocks Is a Buying Opportunity, Say Analysts (TipRanks) -6.50%
Apr-12-21 04:41PM	Oncternal Therapeutics Announces Appointment of Chase Leavitt as General Counsel (GlobeNewswire) -18.16%
07:00AM	Oncternal Therapeutics Announces Presentation of Three Posters at AACR 2021 Virtual Meeting (GlobeNewswire)

Oncternal Therapeutics, Inc. engages in the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Its product pipeline include Zilovertamab, ONCT-216, ONCT-808 and ONCT-534. The company was founded by David F. Hale and James B. Breitmeyer in September 1997 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kaufmann Gunnar F.	Chief Scientific Officer	Jun 14	Buy	0.36	3,000	1,079	94,726	Jun 14 04:00 PM
Kaufmann Gunnar F.	Chief Scientific Officer	Jun 12	Buy	0.35	25,000	8,745	91,726	Jun 14 04:00 PM
BREITMEYER JAMES B	Chief Executive Officer	Apr 14	Buy	0.30	50,000	14,930	196,544	Apr 17 06:00 AM
Yazji Salim	Chief Medical Officer	Apr 14	Buy	0.30	5,000	1,500	164,676	Apr 14 06:02 PM
BREITMEYER JAMES B	Chief Executive Officer	Apr 13	Buy	0.29	100,000	29,000	146,544	Apr 17 06:00 AM
VINCENT RICHARD G	Chief Financial Officer	Apr 13	Buy	0.30	30,000	8,961	156,859	Apr 14 06:00 AM
Leavitt Chase C.	General Counsel/Secretary	Apr 13	Buy	0.29	10,000	2,900	106,901	Apr 14 06:00 AM
Yazji Salim	Chief Medical Officer	Apr 13	Buy	0.28	10,000	2,850	159,676	Apr 14 06:02 PM
Leavitt Chase C.	General Counsel/Secretary	Apr 12	Buy	0.29	15,000	4,350	96,901	Apr 14 06:00 AM
Yazji Salim	Chief Medical Officer	Apr 12	Buy	0.28	10,000	2,850	149,676	Apr 14 06:02 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ONCT

Oncternal Therapeutics Inc

Upgrade your FINVIZ experience